此外，一众知名基石投资者亦为公司市场价值提供背书：包括金域医学、小鹏汽车董事长何小鹏先生， 及明略科技、微盟集团、库洛游戏、手回集团等腾讯生态企业，其中腾讯集团作为公司重要战略股东持 有近20%股份。 此次IPO，卓正医疗可谓收获了资本市场的热烈反响：公开发售阶段获2730.73倍认购，暗盘交易亦持续 火热，富途证券暗盘一度上涨105%，报122.9港元/股，不计手续费每手（50股）最高赚3150港元；老虎 证券暗盘一度涨97%，报118.2港元/股，每手可赚超2915港元。 2025年2月6日，卓正医疗(02677)正式于香港联合交易所主板挂牌上市。上市首日，公司股价大幅飙 涨，盘中最高抵达90.25港元高点，较发行价59.9港元上涨50.67%，最终收于68.5港元。 实际上，资本市场的热烈反馈，早已在另一组数字中埋下了伏笔：2024年，卓正医疗总就诊人次达90 万，平均每位客户年就诊近4次；家庭会员达10.8万户，平均每户会员家庭年消费超过6次；会员续费率 和患者回头率持续攀升，截至2025年8月分别达到67%与82.7%，超八成患者选择复购。 这些数字的背后，是数十万家庭与患者，早早用另一种方式给卓正 ...

南方财经21世纪经济报道记者郑青亭、实习生陈俊康北京报道 摩洛哥—中国商务理事会主席迈赫迪·拉瑞奇则从市场开拓角度分享了心得。他以自身推广摩洛哥橄榄油耗时三年成功立足中国 市场的经历为例，强调"要读懂中国"。他认为，中国市场独具特性，外资企业需充分尊重中国规则与消费习惯，善用微信、淘 宝等本土平台，让产品"被理解、被尊重"，才能在这片广阔市场上扎根成长。 "中国开放的大门正在越开越大，给外国企业带来越来越多的商机。随着中国经济的不断发展，中国市场的吸引力也在不断增 加。"他告诉记者，当前，中国和摩洛哥的合作正在不断深化，很多摩洛哥企业希望与中国企业合作，特别是在供应链方面拓展 合作。 2025年中国国际商会理事会会议（陈俊康/摄） 谈及中美关系，李碧菁认为，今年是两国贸易潜力巨大的一年。若能以两国元首会晤等高层积极互动为契机，推动双边关系发 展，将为商业合作注入更多确定性。"美中关系经历了一段冷淡期，我希望今年能出现更多机会，让美国企业更积极地思考如何 在中国市场创新与发展。"她同时希望看到中国在医疗健康领域的监管、保险支付以及数据共享和科研合作方面继续扩大开放。 本次会议在北京主会场和各地方国际商会分会场线 ...

Summary of Key Points Core Viewpoint - The A-share and Hong Kong stock markets have seen a concentration of new listings, with significant first-day gains for newly listed companies, indicating strong investor interest and market resilience. Group 1: IPO Approvals - Three companies have received IPO approvals this week, all from the Beijing Stock Exchange [2] - Zhejiang Hengdao Technology Co., Ltd. specializes in the research, design, production, and sales of hot runner systems for injection molds, with a major focus on automotive and consumer electronics sectors [3] - Hebi Haichang Intelligent Technology Co., Ltd. focuses on high-performance wiring harness equipment, serving industries such as automotive and renewable energy [5] - Kunshan Hongshida Intelligent Technology Co., Ltd. is engaged in the development and production of intelligent automation equipment for various sectors, including consumer electronics and new energy [6] Group 2: Financial Performance - Hengdao Technology's revenue for 2022-2024 is projected to be 143 million, 168 million, and 234 million yuan, with net profits of 39 million, 49 million, and 69 million yuan respectively [4] - Haichang Intelligent's revenue for the same period is expected to be 520 million, 652 million, and 800 million yuan, with net profits of 108 million, 121 million, and 115 million yuan [5] - Hongshida's revenue is projected to be 397 million, 476 million, and 649 million yuan, with net profits of 30 million, 39 million, and 53 million yuan [7] Group 3: New Listings - "Mingming Hen Mang" (01768.HK), the first stock in the snack retail sector, debuted on January 28, with a first-day closing price increase of 77.52% [9] - Agricultural Technology Company (831038.BJ) listed on the Beijing Stock Exchange, with a first-day closing increase of 1.19% [9] - Zhenstone Co., Ltd. (601112.SH), a leader in clean energy materials, saw its stock price surge by 121.65% on its first day of trading [10] - Medical device company Medela (920119.BJ) also experienced a significant first-day increase of 161.46% [10] Group 4: Filing Dynamics - Eleven companies filed for IPOs in the Hong Kong market this week, with a focus on A+H share expansion [11] - Notable filings include Jucheng Co., a leading non-volatile memory chip designer, and Deyang Co., a leader in energy storage [11] - The trend shows a concentration of hard technology companies seeking to leverage their A-share listings for international financing [12] Group 5: Sector Highlights - Hard technology companies are prominent in the recent IPO filings, with firms like Kunlun New Energy Materials and Coolchip Microelectronics focusing on core material development and AI solutions [12] - Consumer and medical sectors are also active, with companies like Tongrentang and Zhuozheng Medical seeking to expand their service capabilities and market presence [13]

Market Overview - The Federal Reserve maintained interest rates, voting 10 to 2 to keep the federal funds rate in the range of 3.5%-3.75%[13] - The Shanghai Composite Index rose by 0.27% to 4151.24 points, while the Shenzhen Component increased by 0.09%[1] - The Hang Seng Index surged by 2.58% to 27826.91 points, marking its highest level since August 2021[1] Economic Indicators - The U.S. economy shows signs of improvement, with the Fed indicating a more cautious approach to future rate adjustments[13] - Unemployment rates are stabilizing, as noted in the Fed's policy statement[13] - The Hong Kong Monetary Authority reported a record investment return of HKD 331 billion (approximately USD 424 million) for the year 2025, with an 8% return rate[13] Geopolitical Developments - Former President Trump warned Iran to reach a nuclear agreement quickly or face severe military consequences, leading to a spike in oil prices[1] - The U.S. Treasury Secretary denied any intervention in the yen's exchange rate, reaffirming a strong dollar policy, which caused the yen to depreciate by approximately 0.7%[13] Sector Performance - Precious metals, mining, and non-ferrous metals sectors showed strong performance, with significant gains in related stocks[1] - The Hang Seng Technology Index rose by 2.53%, reflecting positive sentiment in the tech sector[1]

Core Viewpoint - The healthcare service industry, traditionally considered "counter-cyclical," is facing pressure due to fluctuating consumer confidence and stringent cost-control policies, leading to profit compression for many medical institutions. However, Zhuozheng Medical, a leading private healthcare brand, shows a contrasting growth trajectory with significant revenue and profit increases projected from 2022 to 2024 [1]. Group 1: Financial Performance - Zhuozheng Medical's revenue is projected to grow from 470 million yuan in 2022 to 960 million yuan in 2024, representing a compound annual growth rate (CAGR) of 42.2% [1]. - The company's gross profit is expected to rise from 43.98 million yuan in 2022 to 230 million yuan in 2024, with a CAGR of 126.7% [1]. - The net profit is forecasted to turn positive in 2024, with figures of -220 million yuan, -350 million yuan, and 80.23 million yuan for the years 2022, 2023, and 2024 respectively, leading to a net profit margin of 8.4% in 2024 [1]. Group 2: Business Model - Zhuozheng Medical does not rely on medical insurance, with only 0.2% of its revenue coming from national medical insurance in 2022 and 2023, and 1.2% in 2024, primarily from a newly acquired hospital [2]. - The company generates over 85% of its revenue from cash payments, allowing for self-pricing and avoiding over-treatment revenue models [3]. - The focus on cash-paying customers has enabled Zhuozheng Medical to maintain positive operating cash flow, exceeding 1 billion yuan in the first eight months of 2025 [3]. Group 3: Customer Acquisition Strategy - Zhuozheng Medical adopts a "slow and steady" approach, relying on word-of-mouth and customer referrals rather than aggressive marketing, with marketing expenses constituting only 2.7%, 1.2%, and 1.7% of revenue from 2022 to 2024 [5]. - The company has a high customer retention rate, with membership renewal rates increasing from 42% in 2022 to 67% in 2025, and patient return rates rising from 75.7% to 82.7% over the same period [6][8]. Group 4: Service Model - Zhuozheng Medical employs a "family multi-specialty" model, addressing common health issues and extending care across various specialties, which increases customer retention and frequency of visits [12]. - In 2024, the average customer visited Zhuozheng Medical nearly four times, significantly higher than typical single-specialty institutions [13]. Group 5: Technology Integration - The company has integrated AI into its operations since 2020, focusing on practical applications rather than following industry trends, which has led to a reduction in labor costs from 80% to 54% of revenue by 2025 [14]. - AI applications have improved operational efficiency, such as automating patient appointment assessments and enhancing diagnostic processes [14]. Group 6: Market Outlook - The private mid-to-high-end healthcare service market in China is projected to grow from 426.4 billion yuan in 2024 to 831.4 billion yuan by 2029, with a CAGR of 14.3%, indicating strong potential for companies like Zhuozheng Medical [16].

Core Viewpoint - The article highlights the unique business model of Zhuozheng Medical, which has achieved significant growth in revenue and profit despite the challenges faced by the healthcare industry due to policy changes and economic pressures. The company has managed to maintain a high growth rate by focusing on cash payments and word-of-mouth marketing rather than relying on insurance reimbursements and traditional advertising methods [2][4][18]. Group 1: Financial Performance - Zhuozheng Medical's revenue is projected to grow from 470 million yuan in 2022 to 960 million yuan in 2024, representing a compound annual growth rate (CAGR) of 42.2% [2]. - The company's gross profit has also increased significantly, with figures of 43.98 million yuan, 130 million yuan, and 230 million yuan over the past three years, achieving a CAGR of 126.7% [2]. - The net profit is expected to turn positive in 2024, with net profits of -220 million yuan, -350 million yuan, and 80.23 million yuan over the last three years, corresponding to net profit margins of -46.8%, -51.2%, and 8.4% [2]. Group 2: Customer Acquisition Strategy - Unlike most private medical institutions that rely on insurance for customer acquisition, Zhuozheng Medical generates approximately 85% of its revenue from cash payments and only about 12% from commercial insurance [4][5]. - The company has maintained low marketing expenses, with marketing costs as a percentage of revenue at 2.7%, 1.2%, and 1.7% from 2022 to 2024, primarily for brand personnel salaries rather than sales [7]. - Customer loyalty is evident with a membership renewal rate of 67% and a patient return rate of 82.7% as of August 2025 [8]. Group 3: Service Model Innovation - Zhuozheng Medical employs a "family multi-specialty" model, addressing the low-frequency nature of healthcare consumption by offering a range of services for common family health needs, thus increasing customer retention [12][14]. - The company has successfully transformed low-frequency visits into high-frequency consumption, with an average of nearly 4 visits per customer in 2024, significantly higher than single-specialty institutions [15]. - The family membership program has led to an average annual consumption of over 6 visits per household, enhancing customer engagement and loyalty [15]. Group 4: Technology Integration - Zhuozheng Medical has been integrating AI into its operations since over three years ago, focusing on practical applications rather than following industry trends [16]. - The company has developed over 270 AI assistants to optimize operations, significantly reducing labor costs from 80% of revenue to 54% by 2025 [16]. - AI applications have improved patient appointment handling and diagnostic efficiency, showcasing a strategic approach to technology adoption [16]. Group 5: Market Potential - The private mid-to-high-end healthcare service market in China is projected to grow from 426.4 billion yuan in 2024 to 831.4 billion yuan in 2029, with a CAGR of 14.3% [18]. - Zhuozheng Medical's innovative business model positions it to capitalize on this growing market, potentially becoming a new force in the health service consumption sector [18].